Your browser doesn't support javascript.
loading
Primary Series and Booster Coronavirus Disease 2019 Vaccine Effectiveness in a Cohort of Healthcare Workers in Albania During a BA.1 and BA.2 Variant Period, January-May 2022.
Finci, Iris; Rojas Castro, Madelyn Yiseth; Hasibra, Iris; Sulo, Jonilda; Fico, Albana; Daja, Rovena; Vasili, Adela; Kota, Majlinda; Preza, Iria; Mühlemann, Barbara; Drosten, Christian; Pebody, Richard; Lafond, Kathryn E; Kissling, Esther; Katz, Mark A; Bino, Silvia.
Afiliación
  • Finci I; Regional Office for Europe, World Health Organization,Copenhagen, Denmark.
  • Rojas Castro MY; Epidemiology Department, Epiconcept, Paris, France.
  • Hasibra I; Department for the Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.
  • Sulo J; Southeast European Center for Surveillance and Control of Infectious Diseases,Tirana, Albania.
  • Fico A; Mediterranean and Black Sea Programme in Intervention Epidemiology Training, European Centre for Disease Prevention and Control, Solna, Sweden.
  • Daja R; Department for the Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.
  • Vasili A; Tirana University Hospital Centre, Tirana, Albania.
  • Kota M; Department for the Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.
  • Preza I; Department for the Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.
  • Mühlemann B; Department for the Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.
  • Drosten C; Country Office Albania, World Health Organization, Tirana, Albania.
  • Pebody R; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health,Berlin, Germany.
  • Lafond KE; German Centre for Infection Research, partner site Charité, Berlin, Germany.
  • Kissling E; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health,Berlin, Germany.
  • Katz MA; German Centre for Infection Research, partner site Charité, Berlin, Germany.
  • Bino S; Regional Office for Europe, World Health Organization,Copenhagen, Denmark.
Open Forum Infect Dis ; 10(10): ofad479, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37885795
ABSTRACT

Background:

Healthcare workers (HCWs) have experienced high rates of coronavirus disease 2019 (COVID-19) morbidity and mortality. We estimated COVID-19 2-dose primary series and monovalent booster vaccine effectiveness (VE) against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (BA.1 and BA.2) infection among HCWs in 3 Albanian hospitals during January-May 2022.

Methods:

Study participants completed weekly symptom questionnaires, underwent polymerase chain reaction (PCR) testing when symptomatic, and provided quarterly blood samples for serology. We estimated VE using Cox regression models (1 - hazard ratio), with vaccination status as the time-varying exposure and unvaccinated HCWs as the reference group, adjusting for potential confounders age, sex, prior SARS-CoV-2 infection (detected by PCR, rapid antigen test, or serology), and household size.

Results:

At the start of the analysis period, 76% of 1462 HCWs had received a primary series, 10% had received a booster dose, and 9% were unvaccinated; 1307 (89%) HCWs had evidence of prior infection. Overall, 86% of primary series and 98% of booster doses received were BNT162b2. The median time interval from the second dose and the booster dose to the start of the analysis period was 289 (interquartile range [IQR], 210-292) days and 30 (IQR, 22-46) days, respectively. VE against symptomatic PCR-confirmed infection was 34% (95% confidence interval [CI], -36% to 68%) for the primary series and 88% (95% CI, 39%-98%) for the booster.

Conclusions:

Among Albanian HCWs, most of whom had been previously infected, COVID-19 booster dose offered improved VE during a period of Omicron BA.1 and BA.2 circulation. Our findings support promoting booster dose uptake among Albanian HCWs, which, as of January 2023, was only 20%. Clinical Trials Registration. NCT04811391.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca